Ipilimumab works to stimulate the body's own immune system to fight prostate cancer
In a multi-site study, Oregon Health and Science University Cancer Institute researchers have found that a drug called ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer.
Researchers at Lund University are developing new methods for treating advanced prostate cancer by attacking stem cell-like cells that allow the disease to survive, spread and resist treatment.